|Bid||16.65 x 1100|
|Ask||21.00 x 2900|
|Day's Range||16.32 - 17.22|
|52 Week Range||11.95 - 26.10|
|Beta (3Y Monthly)||-0.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has entered into a definitive agreement to acquire Perosphere Pharmaceuticals Inc., a private biopharmaceutical company. Through this acquisition, AMAG will acquire global rights to ciraparantag, a next generation anticoagulant reversal agent, further enhancing its development pipeline and leveraging AMAG’s expertise in hematology.
The ASH poster presentation focused on the durability of the improvements in several patient reported outcomes (PRO) measures in patients with iron deficiency anemia (IDA) following a single course of ferumoxytol (2 x 510 mg, 3-8 days apart) over a 6-month extension study period. In the initial phase 3 trial, patients treated with ferumoxytol showed improvement in quality of life compared to placebo as measured by fatigue-related symptoms.
WALTHAM, Mass., Nov. 29, 2018 -- As part of the company’s annual grant program to support research to reduce preterm birth and preeclampsia and associated complications, AMAG.
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
WALTHAM, Mass., Nov. 06, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that company management will participate in the following investor conferences:.
Achieved strong third quarter financial performance and increased full year 2018 guidance Acquired AMAG-423 for severe preeclampsia, reaffirming the.
WALTHAM, Mass., Oct. 25, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its third quarter 2018 financial results will be released on Thursday, November.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
AMAG Pharmaceuticals, Inc. (AMAG) and Endoceutics today announced an oral presentation regarding the effect of time since menopause, age, and previous hormone therapy on treatment efficacy of intravaginal 6.5 mg prasterone (INTRAROSA®) at the Annual Meeting of The North American Menopause Society (NAMS) in San Diego, California. David F. Archer, M.D., NCMP, will present the study results on Thursday, October 4th from 5:15 PM to 5:30 PM. Dr. Archer and colleagues analyzed combined data obtained from two prospective, randomized, double-blind, placebo-controlled clinical trials to evaluate the effect of daily intravaginal 6.5 mg INTRAROSA administered for 12 weeks to women who identified moderate to severe pain at sexual activity (dyspareunia) as their most bothersome symptom (MBS) of vulvar and vaginal atrophy, or VVA.
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has acquired global rights to develop and market digoxin immune Fab (ovine) (DIF), a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women. AMAG and Velo Bio, LLC, a privately held life sciences company located in the Research Triangle Park region of North Carolina, entered into an option agreement in July 2015 to develop DIF.
AMAG Pharmaceuticals, Inc. (AMAG) today announced that together with Emmy®-nominated actress Cheryl Hines and leading family medicine and menopause expert, Marla Shapiro, MD, it is launching an integrated campaign to start an open dialogue about painful sex due to menopause, a topic that is often not talked about among post-menopausal women and their healthcare providers. Vulvar and vaginal atrophy, or VVA, affects approximately 50 percent of postmenopausal women in the United States, and painful sex is one of the potential symptoms.1 Unlike more commonly known symptoms of menopause, such as hot flashes, many women are not aware that painful sex is associated with menopause.
Vyleesi™ New Tradename for Bremelanotide PDUFA Target Action Date of March 23, 2019 for Vyleesi Teleconference and Webcast to be held on September 13, 2018 CRANBURY, N.J. , Sept. 13, 2018 /PRNewswire/ ...
LOS ANGELES , Aug. 6, 2018 /PRNewswire/ -- California Cryobank , the world's leading donor sperm and donor egg bank, announced today that it has been acquired by GI Partners, a private equity investment ...
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:00 AM Eastern ...
LOS ANGELES, June 15, 2018 /PRNewswire/ -- California Cryobank, the world's leading donor sperm and donor egg bank, announced today that it has signed a definitive agreement for GI Partners, a private equity investment firm, to acquire the company from leading healthcare investors Longitude Capital and NovaQuest Capital. In a separate transaction announced today, GI Partners has also entered into a definitive agreement with AMAG Pharmaceuticals, Inc. (AMAG) to acquire Cord Blood Registry (CBR), the world's largest stem cell collection and storage company.
In today's pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and ArQule Inc. (NASDAQ: ARQL). Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday's trading session at $23.95.